SFEBES2018 Poster Presentations Obesity & metabolism (24 abstracts)
Randomised trial of empagliflozin versus metformin in polycystic ovary syndrome
Zeeshan Javed 1, , Maria Papageorgiou 1 , Eric Kilpatrick 3 , Jehangir Abbas 2 , Amer Khan 2 , Alan Rigby 4 , Stephen Atkin 5 & Thozhukat Sathyapalan 1
1University of Hull/Hull York Medical School, Hull, UK; 2Pakistan Kidney and Liver Institute, Lahore, Pakistan; 3Sidra Medical and Research Center, Doha, Qatar; 4University of Hull, Hull, UK; 5Weill Cornell Medical College Qatar, Doha, Qatar.
Background: Empagliflozin is a sodium-glucose-cotransporter-2 that improves cardiovascular risk and weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit in PCOS.
Methods: A randomised, open-label study in 40 overweight and obese women with PCOS treated with either empagliflozin 25 mg or metformin 1500mg daily for 12 weeks.
Results: At 12 weeks empagliflozin treatment resulted in reductions in weight (−1.5±3.3 vs 1.2±2.1; P=0.005), body mass index (−1.4±3.3 vs 1.2±2.1; P=0.005), waist (−1.6±2.8 vs 0.2±2.1; P=0.029) and hip circumference (−2.0±3.0 vs 1.1±1.9; P=0.001) compared to metformin. The percentage reduction from baseline in basal metabolic rate (−1.8%±2.9 vs 0.05±1; P=0.02), fat mass (−0.7%±4.9 vs 3.2%±5.0; P=0.02) and free fat mass (−2.0%±3.2 vs −0.3%±2.2; P=0.05) were greater for empagliflozin compared to metformin treatment. Empagliflozin resulted in an increase in sex hormone binding globulin (P=0.04) while there was significant reduction of total testosterone levels (P=0.04) after metformin treatment only. No changes in endothelial function, free androgen index or insulin resistance were seen between groups.
Conclusion: In this novel study empagliflozin improved anthropometric and body composition parameters, in overweight and obese women with PCOS after 12 weeks of treatment.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more